Feb 5, 2026 07:24AM
Jan 8, 2026 12:08PM
Nov 20, 2025 07:45AM
Jul 3, 2025 07:41AM
Jul 3, 2025 07:40AM
Jun 30, 2025 06:02AM
Jun 30, 2025 06:00AM OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
Jun 24, 2025 07:41AM
Jun 24, 2025 07:40AM
Jun 23, 2025 08:29PM
Jun 10, 2025 07:40AM
Jun 10, 2025 07:40AM
Jun 6, 2025 07:31AM
Jun 6, 2025 07:30AM OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediat
May 16, 2025 06:00AM
May 15, 2025 06:00AM
May 7, 2025 08:45AM
May 7, 2025 08:45AM
May 2, 2025 09:32AM
Apr 22, 2025 07:41AM
Apr 22, 2025 07:40AM OS Therapies FDA Meeting Request Granted
Apr 9, 2025 07:40AM
Apr 9, 2025 07:40AM
Apr 7, 2025 06:00AM
Apr 2, 2025 07:40AM
Mar 31, 2025 04:30PM
Mar 31, 2025 07:40AM
Mar 31, 2025 07:40AM OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Mar 25, 2025 07:40AM
Mar 13, 2025 07:40AM
Mar 11, 2025 07:40AM
Feb 26, 2025 04:01PM
Feb 24, 2025 07:25AM
Feb 24, 2025 07:25AM
Feb 20, 2025 05:54AM OS Therapies (OSTX) Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Feb 20, 2025 05:00AM
Feb 14, 2025 07:36AM
Feb 14, 2025 07:36AM
Feb 4, 2025 07:33AM
Feb 4, 2025 07:33AM
Jan 29, 2025 09:22AM
Jan 15, 2025 07:45AM OS Therapies (OSTX) Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint
Jan 15, 2025 07:40AM
Jan 2, 2025 11:16AM
Dec 31, 2024 03:38PM
Dec 31, 2024 03:38PM
Dec 24, 2024 09:32AM
Dec 24, 2024 09:32AM
Nov 15, 2024 09:47AM OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Oct 28, 2024 04:44PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All